Abstract:Background: The chromodomain helicase DNA-binding protein 2 (CHD2) gene, is an ATPase and part of the CHD family of chromatin remodelers. Mutations in the CHD2 gene are inherited in an autosomal-dominant manner and can lead to intellectual disability, epilepsy, and autism. We investigated the clinical characteristics of CHD2-related conditions and their possible pathogenesis. Methods: We collected and analysed the clinical data of patients that were identified as having CHD2 mutations. Genetic testing was performed using targeted sequencing or whole-exome sequencing. We analysed the expression of CHD2 and repressor element 1-silencing transcription factor (REST) in blood samples using quantitative PCR and the conservation of the mutations. The CHD2 mutations we identified were compared with the known mutations reported in the CHD2-related literature. Results: Eight patients with CHD2 gene mutations were analysed. Six mutations were identified; four were unreported previously (c.670C>T; c.4012A>C; c.2416dup; c.1727-1728insAT), and two were known mutations: c.5035C>T (two cases) and c.4173dup (two cases). Among these mutations, seven were de novo mutations, and one could not be determined because the parents refused genetic testing. The clinical manifestations included mild or severe intellectual disability, epilepsy, and behavioural abnormalities. Quantitative PCR showed that the CHD2 gene expression levels among the patients, parents, and the controls were not significantly different. The levels of REST gene expression in the patients were significantly higher than those of the controls; thus, mutation of the CHD2 gene led to an increase in the expression level of the REST gene. The mutations reported were all located in conserved positions in different species. Among the various medications administered for treatment, valproate showed the best results for the treatment of epilepsy caused by CHD2 gene mutation. Conclusion: Mutation in CHD2 did not lead to a significant decrease in its expression level, indicating that the clinical phenotype was unrelated to its expression level, and the mutant protein may retain some function. Most of the mutations relatively stable. In addition, the clinical manifestations from the same mutation in the CHD2 gene were different among the known cases; this may be related to the regulation of REST or other regulatory factors.

CHD2-epilepsy: Polygraphic documentation of self-induced seizures due to fixation-off sensitivity

CHD2‐related epilepsy with eyelid myoclonia: Report of three cases

Clinical analysis of CHD2 gene mutations in pediatric patients with epilepsy

Aberrant Visual-Related Networks in Familial Cortical Myoclonic Tremor with Epilepsy

CHD2‐related Epilepsy: Novel Mutations and New Phenotypes

Juvenile myoclonic epilepsy mimic associated with CHD2 gene mutation

Autosomal Dominant Sleep-Related Hypermotor Epilepsy Associated with a Novel Mutation of KCNT1.

Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy

CHD2-Related CNS Pathologies

Clinical analysis of five CHD2 gene mutations in Chinese children with epilepsy

A Novel Variant of the CHD2 Gene Associated With Developmental Delay and Myoclonic Epilepsy

CHD2 mutations in Lennox-Gastaut syndrome

SYNGAP1-DEE: A visual sensitive epilepsy

Clinical Study of 8 Cases of <i>CHD2</i> Gene Mutation-Related Neurological Diseases and Their Mechanisms

Clinical Study of 8 Cases of CHD2 Gene Mutation-Related Neurological Diseases and Their Mechanisms

Drug-resistant 'Non-Lesional' Visual Sensitive Epilepsies of Childhood - Electroclinical Phenotype-Genotype Associations

Dissecting genetics of spectrum of epilepsies with eyelid myoclonia by exome sequencing

Novel Loss-of-Function Variants in CHD2 Cause Childhood-Onset Epileptic Encephalopathy in Chinese Patients

Focal cortical dysplasia type 1b as a cause of severe epilepsy with multiple independent spike foci

The epilepsy phenotype of KCNK4-related neurodevelopmental disease

A novel de novo frameshift variant in the CHD2 gene related to intellectual and developmental disability, seizures and speech problems